We are pleased to announce that Schlich has been ranked as a recommended UK firm for patent filings in 2023 by JUVE. Schlich is one of just 25 firms to be recommended, selected for our work in the fields of Medical Technology as well as Pharma and Biotechnology.
Schlich has in particular been noticed for our work on patent filings for some of our well known clients such as AbbVie, Dimension Genomics, Fred Hutchinson Cancer Center, ONK Therapeutics, Vector Vitale, as well as a number of US universities.
Our litigation work in oppositions before the EPO was also highlighted, with notable mentions made to our work on behalf of Intellia Therapeutics in the opposition proceedings over CRISPR-Cas patents against The Broad Institute, Sigma-Aldrich and Toolgen, together with our representation of Glenmark against Towa over the formulation of dabigatran. A further mention was made to our strawman suits for medical devices against Cook Medical, and for Parkinson’s and Alzheimer’s therapy against Centre National de la Recherche Scientifique.
JUVE Patent is an online research tool for the European patent market. It produces rankings of firms in the four main patent jurisdictions in Europe; France, Germany, the UK and the Netherlands; as well as Austria.
We are delighted to have been selected from, and ranked among many prestigious and sizeable firms, a sign of Schlich’s growing success!